The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is included on our list of stocks under $1 that will explode. On December 18, 2025, ...

They make their debuts as Prof. Remus Lupin (Rheon) and Peter Pettigrew (Harrison) in "Prisoner of Azkaban," released by ...

Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.53 per share a year ago. These ...

HOWL reported interim data in November from its phase 1/1b trial of WTX-124 in solid tumors. There are signs of antitumor activity at the 12 mg dose of WTX-124, with two unconfirmed partial responses ...

Werewolf Therapeutics, Inc. develops modified cytokines for cancer treatment, including WTX-124, a modified IL-2, and WTX-330, a modified IL-12. Xilio Therapeutics out-licensed their modified IL-12 to ...